Literature DB >> 17391319

A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress.

Irvin M Modlin1, Manish C Champaneria, Anthony K C Chan, Mark Kidd.   

Abstract

OBJECTIVES: Small intestinal neuroendocrine tumors (SI-NETs) are the most common gastrointestinal neuroendocrine tumor, but their natural history and outcome remain poorly defined, which hinders both the prediction of disease progression and appropriate therapeutic options. We examined patterns, incidence, prognosis, and outcomes of these tumors over a 30-yr period.
METHODS: Data were extracted from the NCI's SEER registry (1973-2002). Incidence rates, distribution, and 5-yr survival rates were analyzed and adjusted (U.S. decennial census data).
RESULTS: Of the 18,641 NETs, 3,911 (21.0%) were SI-NETs, of which 1,953 (49.6%) were ileal. Since 1973, both SI-NET and its ileal variant have increased annually by 3.8% and 2.1%, respectively. Ileal tumors, as a percentage of SI tumors, have increased from 52% to 63.6%. The age-adjusted incidence of ileal, small intestinal, and digestive system NETs has increased 225%, 460%, and 720% over 30 yr. Ileal tumors have specifically increased in prevalence in white (274%) and black (500%) men and women (213% and 286%, respectively); an overall increase of fourfold in blacks and 2.4-fold in whites. Although 83.3% of SI-NETs were staged, 83.7% were histologically ungraded. Five-year survival rates for SI-NETs were 62.6 +/- 1% (all stages), 73.8% (localized), 72% (regional), and 43.2% (distant). These have not significantly altered since 1973 (P= 0.11).
CONCLUSIONS: SI-NETs have increased, particularly in men and in the black population, which may be due to in vivo changes, increased clinical and pathological awareness, or increased detection of tumors. SI-NETs are malignant, diagnosed late, and survival rates have remained unchanged over 30 yr.

Entities:  

Mesh:

Year:  2007        PMID: 17391319     DOI: 10.1111/j.1572-0241.2007.01185.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  51 in total

1.  Should mesenteric tumor deposits be included in staging of well-differentiated small intestine neuroendocrine tumors?

Authors:  Raul S Gonzalez; Eric H Liu; JoAnn R Alvarez; Gregory D Ayers; M Kay Washington; Chanjuan Shi
Journal:  Mod Pathol       Date:  2014-01-24       Impact factor: 7.842

2.  Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center.

Authors:  Olov Norlén; Peter Stålberg; Kjell Öberg; John Eriksson; Jakob Hedberg; Ola Hessman; Eva Tiensuu Janson; Per Hellman; Göran Åkerström
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

3.  Neglected conditions: Neuroendocrine tumours.

Authors:  Julie Hallet; Simron Singh; Calvin H L Law
Journal:  CMAJ       Date:  2014-04-01       Impact factor: 8.262

Review 4.  Management of gastric and duodenal neuroendocrine tumors.

Authors:  Yuichi Sato; Satoru Hashimoto; Ken-Ichi Mizuno; Manabu Takeuchi; Shuji Terai
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

5.  CTGF, intestinal stellate cells and carcinoid fibrogenesis.

Authors:  M Kidd; I M Modlin; M D Shapiro; R L Camp; S M Mane; W Usinger; J R Murren
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

6.  Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor.

Authors:  Martha Frances Wright; Justin Cates; Raul S Gonzalez; Satya Das; Jordan D Berlin; Chanjuan Shi
Journal:  Am J Surg Pathol       Date:  2019-04       Impact factor: 6.394

7.  Inferior Vena Cava Syndrome as a Manifestation of Metastatic Carcinoid Tumor.

Authors:  Matthew Stankard; Erik Soule; Jerry Matteo
Journal:  Gastrointest Tumors       Date:  2021-04-13

Review 8.  [Indications and operative procedures for neuroendocrine liver metastases].

Authors:  T J Musholt; H Lang
Journal:  Chirurg       Date:  2009-02       Impact factor: 0.955

9.  Update on management of midgut neuroendocrine tumors.

Authors:  Amir Mehrvarz Sarshekeh; Daniel M Halperin; Arvind Dasari
Journal:  Int J Endocr Oncol       Date:  2016-04-08

Review 10.  The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.

Authors:  Anne Klibanski; Shlomo Melmed; David R Clemmons; Annamaria Colao; Regina S Cunningham; Mark E Molitch; Aaron I Vinik; Daphne T Adelman; Karen J P Liebert
Journal:  Pituitary       Date:  2010-09       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.